Jeffrey B Geske1, Kevin C Ong1, Konstantinos C Siontis2, Virginia B Hebl1, Michael J Ackerman1,3,4, David O Hodge5, Virginia M Miller6, Rick A Nishimura1, Jae K Oh1, Hartzell V Schaff7, Bernard J Gersh1, Steve R Ommen1. 1. Department of Cardiovascular Diseases, Mayo Clinic, 200 First St. S.W., Rochester, MN 55905, USA. 2. Department of Internal Medicine, Mayo Clinic, 200 First St. S.W., Rochester, MN 55905, USA. 3. Department of Pediatrics, Mayo Clinic, 200 First St. S.W., Rochester, MN 55905, USA. 4. Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, 200 First St. S.W., Rochester, MN 55905, USA. 5. Department of Biomedical Statistics and Informatics, Mayo Clinic, 200 First St. S.W., Rochester, MN 55905, USA. 6. Women's Health Research Center, Mayo Clinic, 200 First St. S.W., Rochester, MN 55905, USA. 7. Department of Cardiovascular Surgery, Mayo Clinic, 200 First St. S.W., Rochester, MN 55905, USA.
Abstract
AIMS: Sex differences in hypertrophic cardiomyopathy (HCM) remain unclear. We sought to characterize sex differences in a large HCM referral centre population. METHODS AND RESULTS: Three thousand six hundred and seventy-three adult patients with HCM underwent evaluation between January 1975 and September 2012 with 1661 (45.2%) female. Kaplan-Meier survival curves were assessed via log-rank test. Cox proportional hazard regression analyses evaluated the relation of sex with survival. At index visit, women were older (59 ± 16 vs. 52 ± 15 years, P < 0.0001) had more symptoms [New York Heart Association (NYHA) Class III-IV 45.0% vs. 35.3%, P < 0.0001], more obstructive physiology (77.4% vs. 71.8%, P = 0.0001), more mitral regurgitation (moderate or greater in 56.1% vs. 43.9%, P < 0.0001), higher E/e' ratio (n = 1649, 20.6 vs. 15.6, P < 0.0001), higher estimated pulmonary artery systolic pressure (n = 1783, 40.8 ± 15.4 vs. 34.8 ± 10.8 mmHg, P < 0.0001), worse cardiopulmonary exercise performance (n = 1267; percent VO2 predicted 62.8 ± 20% vs. 65.8 ± 19.2%, P = 0.007), and underwent more frequent alcohol septal ablation (4.9% vs. 3.0%, P = 0.004) but similar frequency of myectomy (28% vs. 30%, P = 0.24). Median follow-up was 10.9 (IQR 7.4-16.2) years. Kaplan-Meier analysis demonstrated lower survival in women compared with men (P < 0.0001). In multivariable modelling, female sex remained independently associated with mortality (HR 1.13 [1.03-1.22], P = 0.01) when adjusted for age, NYHA Class III-IV symptoms, and cardiovascular comorbidities. CONCLUSION: Women with HCM present at more advanced age, with more symptoms, worse cardiopulmonary exercise tolerance, and different haemodynamics than men. Sex is an important determinant in HCM management as women with HCM have worse survival. Women may require more aggressive diagnostic and therapeutic approaches. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Sex differences in hypertrophic cardiomyopathy (HCM) remain unclear. We sought to characterize sex differences in a large HCM referral centre population. METHODS AND RESULTS: Three thousand six hundred and seventy-three adult patients with HCM underwent evaluation between January 1975 and September 2012 with 1661 (45.2%) female. Kaplan-Meier survival curves were assessed via log-rank test. Cox proportional hazard regression analyses evaluated the relation of sex with survival. At index visit, women were older (59 ± 16 vs. 52 ± 15 years, P < 0.0001) had more symptoms [New York Heart Association (NYHA) Class III-IV 45.0% vs. 35.3%, P < 0.0001], more obstructive physiology (77.4% vs. 71.8%, P = 0.0001), more mitral regurgitation (moderate or greater in 56.1% vs. 43.9%, P < 0.0001), higher E/e' ratio (n = 1649, 20.6 vs. 15.6, P < 0.0001), higher estimated pulmonary artery systolic pressure (n = 1783, 40.8 ± 15.4 vs. 34.8 ± 10.8 mmHg, P < 0.0001), worse cardiopulmonary exercise performance (n = 1267; percent VO2 predicted 62.8 ± 20% vs. 65.8 ± 19.2%, P = 0.007), and underwent more frequent alcohol septal ablation (4.9% vs. 3.0%, P = 0.004) but similar frequency of myectomy (28% vs. 30%, P = 0.24). Median follow-up was 10.9 (IQR 7.4-16.2) years. Kaplan-Meier analysis demonstrated lower survival in women compared with men (P < 0.0001). In multivariable modelling, female sex remained independently associated with mortality (HR 1.13 [1.03-1.22], P = 0.01) when adjusted for age, NYHA Class III-IV symptoms, and cardiovascular comorbidities. CONCLUSION: Women with HCM present at more advanced age, with more symptoms, worse cardiopulmonary exercise tolerance, and different haemodynamics than men. Sex is an important determinant in HCM management as women with HCM have worse survival. Women may require more aggressive diagnostic and therapeutic approaches. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Paul Sorajja; Uma Valeti; Rick A Nishimura; Steve R Ommen; Charanjit S Rihal; Bernard J Gersh; David O Hodge; Hartzell V Schaff; David R Holmes Journal: Circulation Date: 2008-07-08 Impact factor: 29.690
Authors: Alexander H Maass; Kaori Ikeda; Silke Oberdorf-Maass; Sebastian K G Maier; Leslie A Leinwand Journal: Circulation Date: 2004-10-04 Impact factor: 29.690
Authors: Kathryn M King; William A Ghali; Peter D Faris; Michael J Curtis; P Diane Galbraith; Michelle M Graham; Merril L Knudtson Journal: JAMA Date: 2004-03-10 Impact factor: 56.272
Authors: J Martijn Bos; Jeanne L Theis; A Jamil Tajik; Bernard J Gersh; Steve R Ommen; Michael J Ackerman Journal: Am Heart J Date: 2008-02-21 Impact factor: 4.749
Authors: S Dey; M D Flather; G Devlin; D Brieger; E P Gurfinkel; P G Steg; G Fitzgerald; E A Jackson; K A Eagle Journal: Heart Date: 2008-05-07 Impact factor: 5.994
Authors: Zahara Meghji; Anita Nguyen; Benish Fatima; Jeffrey B Geske; Rick A Nishimura; Steve R Ommen; Brian D Lahr; Joseph A Dearani; Hartzell V Schaff Journal: JAMA Cardiol Date: 2019-03-01 Impact factor: 14.676
Authors: Ella Field; Gabrielle Norrish; Vanessa Acquaah; Kathleen Dady; Marcos Nicolas Cicerchia; Juan Pablo Ochoa; Petros Syrris; Karen McLeod; Ruth McGowan; Hannah Fell; Luis R Lopes; Elena Cervi; Juan Pablo Pablo Kaski Journal: J Med Genet Date: 2021-08-16 Impact factor: 5.941
Authors: Joshua R Smith; Jose R Medina-Inojosa; Veronica Layrisse; Steve R Ommen; Thomas P Olson Journal: J Clin Med Date: 2018-11-18 Impact factor: 4.241